February 18, 2026 8:00 AM EST | Source: Marvel Biosciences Corp. Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce ...
Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for ...
(RTTNews) - Clearmind Medicine Inc. (CMND), Wednesday announced that the company has signed a non-binding Letter of Intent with Polyrizon Ltd. (PLRZ), a development stage biotech company, to develop a ...
Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary MEAI Raanana, Israel, Feb. 06, ...
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results